Table 1.
Clinical characteristics of 113 vaccinated HM patients that developed COVID-19 infection
| Patients, n | % | |
|---|---|---|
| Sex | ||
| Female/male | 44/69 | 38.9/61.1 |
| Age (y.o.) (IQR) [range] | 66 (58 - 78) [21 - 94] | |
| 50/>50 y.o. | 16/97 | 14.2/85.8 |
| Comorbidities | ||
| None/1-2-3 comorbidities | 36/77 | 31.9/68.1 |
| Smoking history | 17 | 15.0 |
| Malignancy | ||
| Acute lymphoid leukemia | 3 | 2.6 |
| Chronic lymphoid leukemia | 28 | 24.8 |
| Acute myeloid leukemia | 5 | 4.4 |
| Chronic myeloid leukemia | 1 | 0.9 |
| Myelodysplastic syndrome | 7 | 6.2 |
| Hodgkin lymphoma | 4 | 3.5 |
| Non-Hodgkin lymphoma | 36 | 31.9 |
| Myelofibrosis | 3 | 2.7 |
| Polycythemia vera | 2 | 1.8 |
| Systemic mastocytosis | 2 | 1.8 |
| Multiple myeloma | 20 | 17.7 |
| Aplastic anemia | 2 | 1.8 |
| Malignancy status before COVID-19 | ||
| Controlled disease* | 51 | 45.1 |
| Active disease | 60 | 53.1 |
| Not reported | 2 | 1.8 |
| Last malignancy treatment (in the last 3 mo) | ||
| alloHSCT (in the last 6 mo) | 1 | 0.9 |
| Chemotherapy | 77 | 68.1 |
| Conventional chemotherapy | 13 | 11.5 |
| Hypomethylating agents | 4 | 3.5 |
| Immunotherapy | 9 | 8.0 |
| Immunochemotherapy | 30 | 26.5 |
| Targeted therapy | 21 | 18.6 |
| No treatment | 35 | 31.0 |
| Patients with previous COVID-19 infections | 2 | 1.8 |
| Yes/no | 2/111 | 1.8/98.2 |
| Vaccination | ||
| One dose | 25 | 22.1 |
| Two doses | 88 | 77.8 |
| Patient that received vaccination at least 14 d before COVID-19 infection | 87 | 77.0 |
| Type of vaccine | ||
| mRNA + LNP | ||
| BioNTech/Pfizer | 79 | 69.9 |
| Moderna COVE | 20 | 17.7 |
| Vector-based | ||
| AstraZeneca Oxford | 10 | 8.8 |
| Inactivated | ||
| Sinovac | 4 | 3.5 |
| Antispike protein Ig dosage after vaccination (referring to WHO international standards, BAU/mL) | ||
| No response (<30) | 27 | 23.9 |
| Weak response (31-250) | 5 | 4.4 |
| Optimal response (>250) | 8 | 7 |
| Unknown/not measured | 73 | 64.7 |
| COVID-19 infection | ||
| WT | 11 | 9.7 |
| English: alpha (α) | 16 | 14.2 |
| South African: beta (β) | 1 | 0.9 |
| Indian: delta (δ) | 9 | 8.0 |
| Not tested | 76 | 67.3 |
| Severity | ||
| Asymptomatic | 22 | 19.5 |
| Mild infection | 12 | 10.6 |
| Severe infection | 63 | 55.8 |
| Critical infection | 16 | 14.2 |
| Symptomatology at onset | ||
| Asymptomatic | 23 | 20.4 |
| Pulmonary symptoms | 37 | 32.7 |
| Extrapulmonary symptoms | 14 | 12.4 |
| Pulmonary and extrapulmonary | 39 | 34.5 |
| Neutrophil count | ||
| ≥500/mm3 | 98 | 86.7 |
| Lymphocyte count | ||
| ≥200/mm3 | 92 | 81.4 |
alloHSCT, allogeneic hematopoietic stem cell transplantation; BAU, binding antibody units; COVE, Coronavirus Efficacy and Safety Study; IQR, interquartile range; LNP, lipid nanoparticles; mRNA, messenger RNA; N, number; WT, wild type; y.o., years old.
*
Controlled disease: partial remission or better.